Estrogens, estrogen receptors and melanoma

References

• Thornton MJ. The biological actions of estrogens on skin. Exp. Dermatol.11, 487–502 (2002).
   PubMed Web of Science ®Google Scholar
• Verdier-Sevrain S, Bonte F, Gilchrest B. Biology of estrogensin skin: implications for skin aging. Exp. Dermatol.15, 83–94 (2006).
   PubMed Web of Science ®Google Scholar
• Raine-Fenning NJ, Brincat MP, Muscat-Baron Y. Skin aging and menopause: implications for treatment. Am. J. Clin. Dermatol.4, 371–378 (2003).
   PubMed Web of Science ®Google Scholar
• Hall G, Phillips TJ. Estrogen and skin: the effects of estrogen, menopause, and hormone replacement therapy on the skin. J. Am. Acad. Dermatol.53(4), 555–566 (2005).
   PubMed Web of Science ®Google Scholar
• Stevenson S, Thornton J. Effect of estrogens on skin aging and the potential role of SERMs. Clin. Interv. Aging2(3), 283–297 (2007).
   PubMed Web of Science ®Google Scholar
• Sator PG, Schmidt JB, Sator MO, Huber JC, Honingsmann H. The influence of hormone replacement therapy on skin aging: a pilot study. Maturitas39, 43–55 (2001).
   PubMed Web of Science ®Google Scholar
• Zouboulis CC, Chen WC, Thornton MJ, Qin K, Rosenfield R. Sexual hormones in human skin. Horm. Metab. Res.39(2), 85–95 (2007).
   PubMed Web of Science ®Google Scholar
• Dao H Jr, Kazin RA. Gender differences in skin: a review of the literature. Gend. Med.4(4), 308–328 (2007).
   PubMedGoogle Scholar
• Russo IH, Russo J. Role of hormones in mammary cancer initiation and progression. J. Mammary Gland Biol. Neoplasia3(1), 49–61 (1998).
   PubMed Web of Science ®Google Scholar
• Di Leo A, Messa C, Cavallini A, Linsalata M. Estrogens and colorectal cancer. Curr. Drug. Targets Immune Endocr. Metab. Disord.1, 1–12 (2001).
   PubMedGoogle Scholar
• Pujol P, Rey JM, Nirde P et al. Differential expression of estrogen receptor-α and -β messenger RNAs as a potential marker of ovarian carcinogenesis. Cancer Res.58, 5367–5373 (1998).
   PubMed Web of Science ®Google Scholar
• Beatson C. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet2, 104–107 (1896).
   Google Scholar
• Jensen E, Jacobson HI. Fate of steroidal estrogens in target tissues. In: Biological Activities of Steroids in Relation to Cancer. Pincus G, Vollmer EP (Eds.). Academic Press, NY, USA, 161–174 (1960).
   Google Scholar
• Jensen E, Jacobson HI. Basic guides to the mechanism of estrogen action. Recent Prog. Horm. Res.18, 387–414 (1962).
   Google Scholar
• Walter P, Green S, Greene G et al. Cloning of the human estrogen receptor cDNA. Proc. Natl Acad. Sci. USA82, 7889–7893 (1985).
   PubMed Web of Science ®Google Scholar
• Green S, Walter P, Kumar V et al. Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature320, 134–139 (1986).
   PubMed Web of Science ®Google Scholar
• Greene GL, Gilna P, Waterfield M, Baker A, Hort Y, Shine J. Sequence and expression of the human estrogen receptor complementary DNA. Science231, 1150–1154 (1986).
   PubMed Web of Science ®Google Scholar
• Green S, Walter P, Greene G et al. Cloning of the human estrogen receptor cDNA. J. Steroid Biochem.24, 77–83 (1986).
   PubMedGoogle Scholar
• Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. Cloning of a novel receptor expressed in rat prostate and ovary. Proc. Natl Acad. Sci. USA93, 5925–5930 (1996).
   PubMed Web of Science ®Google Scholar
• Tremblay GB, Tremblay A, Copeland NG et al. Cloning, chromosomal localization, and functional analysis of the murine estrogen receptorβ. Mol. Endocrinol.11, 353–365 (1997).
   PubMed Web of Science ®Google Scholar
• Mosselman S, Polman J, Dijkema R. ERβ: identification and characterization of a novel human estrogen receptor. FEBS Lett.392, 49–53 (1996).
   PubMed Web of Science ®Google Scholar
• Ponglikitmongkol M, Green S, Chambon P. Genomic organization of the human oestrogen receptor gene. EMBO J.7, 3385–3388 (1988).
   PubMed Web of Science ®Google Scholar
• Enmark E, Pelto-Huikko M, Grandien K et al. Human estrogen receptor β-gene structure, chromosomal localization, and expression pattern. J. Clin. Endocrinol. Metab.82, 4258–4265 (1997).
   PubMed Web of Science ®Google Scholar
• Benecke A, Chambon P, Gronemeyer H. Synergy between estrogen receptor α activation functions AF-1 and AF-2 mediated by transcription intermediary factors TIF2. EMBO Rep.1(2), 151–157 (2000).
   PubMedGoogle Scholar
• Wissink S, van der Burg B, Katzenellenbogen BS, van der Saag PT. Synergistic activation of the serotonin-1A receptor by nuclear factor-κB and estrogen. Mol. Endocrinol.15, 543–552 (2001).
   PubMedGoogle Scholar
• Zhao C, Dahlman-Wright K, Gustafsson JA. Estrogen signaling via estrogen receptor β. J. Biol. Chem.285(51), 39575–39579 (2010).
   PubMed Web of Science ®Google Scholar
• Roger P, Sahla ME, Mäkelä S, Gustafsson JA, Baldet P, Rochefort H. Decreased expression of estrogen receptor β protein in proliferative preinvasive mammary tumors. Cancer Res.61(6), 2537–2541 (2001).
   PubMed Web of Science ®Google Scholar
• Gustafsson JA, Warner M. Estrogen receptor β in the breast: role in estrogen responsiveness and development of breast cancer. J. Steroid Biochem. Mol. Biol.74(5), 245–248 (2000).
   PubMedGoogle Scholar
• Thomas CG, Ström A, Lindberg K, Gustafsson JA. Estrogen receptor β decreases survival of p53-defective cancer cells after DNA damage by impairing G(2)/M checkpoint signaling. Breast Cancer Res. Treat. DOI: 10.1007/s10549–010–1011-z (2010) (Epub ahead of print).
   Google Scholar
• Hartman J, Edvardsson K, Lindberg K, Zhao C, Williams C, Ström A, Gustafsson JA. Tumor repressive functions of estrogen receptor β in SW480 colon cancer cells. Cancer Res.69(15), 6100–6106 (2009).
   PubMedGoogle Scholar
• Lindberg K, Ström A, Lock JG, Gustafsson JA, Haldosén LA, Helguero LA. Expression of estrogen receptor beta increases integrin α1 and integrin β1 levels and enhances adhesion of breast cancer cells. J. Cell Physiol.222(1), 156–167 (2010).
   PubMed Web of Science ®Google Scholar
• Taylor AH, Al-Azzawi F. Immunolocalisation of oestrogen receptor β in human tissues. J. Mol. Endocrinol.24, 145–155 (2000).
   PubMed Web of Science ®Google Scholar
• Brandenberger AW, Tee MK, Lee JY, Chao V, Jaffe RB. Tissue distribution of estrogen receptor α (ER-α) and β (ER-β) mRNA in the midgestational human fetus. J. Clin. Endocrinol. Metab.82, 3509–3512 (1997).
   PubMed Web of Science ®Google Scholar
• Thornton MJ, Taylor AH, Mulligan K et al. Oestrogen receptor β is the predominant oestrogen receptor in human scalp skin. Exp. Dermatol.12, 181–190 (2003).
   PubMed Web of Science ®Google Scholar
• Pelletier G, Ren L. Localization of sex steroid receptors in human skin. Histol. Histopathol.19, 629–636 (2004).
   PubMed Web of Science ®Google Scholar
• Taylor AH, Guzail M, Al-Azzawi F. Differential expression of oestrogen receptor isoforms and androgen receptor in the normal vulva and vagina compared with vulval lichen sclerosus and chronic vaginitis. Br. J. Dermatol.158, 319–328 (2008).
   PubMed Web of Science ®Google Scholar
• Kariya Y, Moriya T, Suzuki T et al. Sex steroid hormone receptors in human skin appendage and its neoplasms. Endocr. J.52, 317–325 (2005).
   PubMed Web of Science ®Google Scholar
• Moverare S, Lindberg MK, Faegermann J et al. Estrogen receptor α, but not estrogen receptor β, is involved in the regulation of the hair follicle cycling as well as the thickness of epidermis in male mice. J. Invest. Dermatol.124, 22–27 (2002).
   Google Scholar
• Chang KC, Wang Y, Oh IG et al. Estrogen receptor β is a novel therapeutic target for photoaging. Mol. Pharmacol.77, 744–750 (2010).
   PubMedGoogle Scholar
• Ghersetich I, Troiano M, De Giorgi V, Lotti T. Receptors in skin ageing and antiageing agents. Dermatol. Clin.25(4), 655–662, xi (2007).
   PubMedGoogle Scholar
• El Safoury O, Rashid L, Ibrahim M. A study of androgen and estrogen receptors α, β in skin tags. Indian J. Dermatol.55(1), 20–24 (2010).
   PubMedGoogle Scholar
• Strouse JJ, Fears TR, Tucker MA et al. Pediatric melanoma: risk factor and survival analysis of the Surveillance, Epidemiology, and End Results database. J. Clin. Oncol.23, 4735–4741 (2005).
   PubMed Web of Science ®Google Scholar
• Kemeny MM, Busch E, Stewart AK, Menck HR. Superior survival of young women with malignant melanoma. Am. J. Surg.175(6), 437–444 (1998).
   PubMed Web of Science ®Google Scholar
• Scoggins CR, Ross MI, Reintgen DS et al.; for the Sunbelt Melanoma Trial. Gender-related differences in outcome for melanoma patients. Ann. Surg.243, 693–698 (2006).
   PubMed Web of Science ®Google Scholar
• Joosse A, de Vries E, Eckel R et al. Gender differences in melanoma survival: female patients have a decreased risk of metastasis. J. Invest. Dermatol.131(3), 719–726 (2011).
   PubMed Web of Science ®Google Scholar
• Miller JG, Mac Neil S. Gender and cutaneous melanoma. Br. J. Dermatol.136(5), 657–665 (1997).
   PubMed Web of Science ®Google Scholar
• Miller JG, Gee J, Price A, Garbe C, Wagner M, Mac Neil S. Investigation of oestrogen receptors, sex steroids and soluble adhesion molecules in the progression of malignant melanoma. Mel. Res.7, 197–208 (1997).
   PubMed Web of Science ®Google Scholar
• Smith MA, Fine JA, Barnhill RL, Berwick M. Hormonal and reproductive influences and risk of melanoma in women. Intern. J. Epidemiol.27, 751–757 (1998).
   PubMed Web of Science ®Google Scholar
• Koomen ER, Joosse A, Herings RM, Casparie MK, Guchelaar HJ, Nijsten T. Does the use of estrogens decrease the Breslow thickness of melanoma of the skin? Oral contraceptives and hormonal replacement therapy. Mel. Res.19(5), 327–332 (2009).
   PubMedGoogle Scholar
• Beral V, Ramcharan S, Faris R. Malignant melanoma and oral contraceptive use among women in California. Br. J. Cancer36, 804–809 (1977).
   PubMed Web of Science ®Google Scholar
• Ramcharan S, Pellegrin FA, Ray R et al. The Walnut Creek Contraceptive Drug Study (Volume III). Center for Population Research, National Institute of Health, Bethesda, MD, USA (1981).
   Google Scholar
• Feskanich D, Hunter DJ, Willett WC et al. Oral contraceptive use and risk of melanoma in premenopausal women. Br. J. Cancer81, 918–923 (1999).
   PubMed Web of Science ®Google Scholar
• Koomen ER, Joosse A, Herings RM, Casparie MK, Guchelaar HJ, Nijsten T. Estrogens, oral contraceptives and hormonal replacement therapy increase the incidence of cutaneous melanoma: a population based case–control study. Ann. Oncol.20, 358–364 (2009).
   PubMedGoogle Scholar
• Adam SA, Sheaves SA, Wright NH et al. A case–control study of the possible association between oral contraceptives and malignantmelanoma. Br. J. Cancer44, 45–50 (1981).
   PubMed Web of Science ®Google Scholar
• Bain C, Hennekens Ch, Speizer FE et al. Oral contraceptive use and malignant melanoma. J. Natl Cancer Inst.68, 537–539 (1982).
   PubMed Web of Science ®Google Scholar
• Holly EA, Weiss NS, Liff JM. Cutaneous melanoma in relation to exogenous hormones and reproductive factors. J. Natl Cancer Inst.70, 827–831 (1983).
   PubMedGoogle Scholar
• Beral V, Evans S, Shaw H et al. Oral contraceptive use and malignant melanoma in Australia. Br. J. Cancer50, 681–685 (1984).
   PubMed Web of Science ®Google Scholar
• Holman CDJ, Armstrong BK, Heenan PJ. Cutaneous malignant melanoma in women: exogenous sex hormones and reproductive factors. Br. J. Cancer50, 673–680 (1984).
   PubMed Web of Science ®Google Scholar
• Helmrich SP, Rosenberg L, Kaufman DW et al. Lack of an elevated risk of malignant melanoma in relation to oral contraceptive use. J. Natl. Cancer Inst.72, 617–620 (1984).
   PubMedGoogle Scholar
• Gallagher RP, Elwood JM, Hill GB et al. Reproductive factors, oral contraceptives and risk of malignant melanoma: Western Canada melanoma study. Br. J. Cancer52, 901–907 (1985).
   PubMed Web of Science ®Google Scholar
• Green A, Bain C. Hormonal factors and melanoma in women. Med. J. Aust.142, 446–448 (1985).
   PubMed Web of Science ®Google Scholar
• Osterlind A, Tucker MA, Stone BJ et al. The Danish case–control study of cutaneous malignant melanoma. III. Hormonal and reproductive factors in women. Int. J. Cancer42, 821–824 (1988).
   PubMed Web of Science ®Google Scholar
• Zanetti R, Franceschi S, Rosso S et al. Cutaneous malignant melanoma in females: the role of hormonal and reproductive factors. Int. J. Epidemiol.19, 522–526 (1990).
   PubMed Web of Science ®Google Scholar
• Hannaford PC, Villard-Mackintosh L, Vessey MP et al. Oral contraceptives and malignant melanoma. Br. J. Cancer63, 430–433 (1991).
   PubMedGoogle Scholar
• Lê MG, Cabanes PA, Desvignes V et al. Oral contraceptive use and risk of cutaneous malignant melanoma in a case–control study of French women. Cancer Causes Control3, 199–205 (1992).
   PubMedGoogle Scholar
• Palmer JR, Rosenberg L, Strom BL et al. Oral contraceptive use and risk of cutaneous malignant melanoma. Cancer Causes Control3, 547–554 (1992).
   PubMedGoogle Scholar
• Holly EA, Cress RD, Ahn DK. Cutaneous melanoma in women. III. Reproductive factors and oral contraceptive use. Am. J. Epidemiol.141, 943–950 (1995).
   PubMedGoogle Scholar
• Westerdahl J, Olsson H, Masback A et al. Risk of malignant melanoma in relation to drug intake, alcohol, smoking and hormonal factors. Br. J. Cancer73, 1126–1131 (1996).
   PubMed Web of Science ®Google Scholar
• Lea CS, Holly EA, Hartge P et al. Reproductive risk factors for cutaneous melanoma in women: a case–control study. Am. J. Epidemiol.165, 505–513 (2007).
   PubMedGoogle Scholar
• Naldi L, Altieri A, Imberti GL et al. Cutaneous malignant melanoma in women. Phenotypic characteristics, sun exposure, and hormonal factors: a case–control study from Italy. Ann. Epidemiol.15, 545–550 (2005).
   PubMedGoogle Scholar
• Osterlind A. Hormonal and reproductive factors in melanoma risk. Clin. Dermatol.10(1), 75–78 (1992).
   PubMedGoogle Scholar
• Gupta A, Driscoll MS. Do hormones influence melanoma? Facts and controversies. Clin. Dermatol.28(3), 287–292 (2010).
   PubMedGoogle Scholar
• Lens M, Bataille V. Melanoma in relation to reproductive and hormonal factors in women: current review on controversial issues. Cancer Causes Control19(5), 437–442 (2008).
   PubMedGoogle Scholar
• Gefeller O, Hassan K, Wille L. Cutaneous malignant melanoma in women and the role of oral contraceptives. Br. J. Dermatol.38, 122–124 (1998).
   Google Scholar
• Pfahlberg A, Hassan K, Wille L et al. Systematic review of case–control studies: oral contraceptives show no effect on melanoma risk. Public Health Rev.25, 309–315 (1997).
   PubMedGoogle Scholar
• Karagas MR, Stuckel TA, Dykes J et al. A pooled analysis of 10 case–control studies of melanoma and oral contraceptive use. Br. J. Cancer86, 1085–1092 (2002).
   PubMed Web of Science ®Google Scholar
• Holly EA, Cress RD, Ahn DK. Cutaneous melanoma in women: ovulatory life, menopause, and use of exogenous estrogens. Cancer Epidemiol. Biomarkers Prev.3, 661–668 (1994).
   PubMedGoogle Scholar
• MacKie RM, Bray CA. Hormone replacement therapy after surgery for stage 1 or 2 cutaneous melanoma. Br. J. Cancer90, 770–772 (2004).
   PubMed Web of Science ®Google Scholar
• Persson I, Yuen J, Bergkvist L, Schairer C. Cancer incidence and mortality in women receiving estrogen and estrogen–progestin replacement therapy – long-term follow-up of a Swedish cohort. Int. J. Cancer67, 327–332 (1996).
   PubMed Web of Science ®Google Scholar
• Lens MB, Rosdahl I, Ahlbom A et al. Effect of pregnancy on survival in women with cutaneous malignant melanoma. J. Clin. Oncol.22(21), 4369–4375 (2004).
   PubMedGoogle Scholar
• Pack GT, Scharnagel IM. The prognosis for malignant melanoma in the pregnant woman. Cancer4, 324–334 (1951).
   PubMedGoogle Scholar
• Riberti C, Marola G, Bertani A. Malignant melanoma: the adverse effect of pregnancy. Br. J. Plastic Surg.34, 338–339 (1981).
   PubMedGoogle Scholar
• Miller E, Barnea Y, Gur E et al. Malignant melanoma and pregnancy: second thoughts. J. Plast. Reconstr. Aesthet. Surg.20, 1–6 (2009).
   Google Scholar
• Kaae J, Andersen A, Boyd HA, Wohlfahrt J, Melbye M. Reproductive history and cutaneous malignant melanoma: a comparison between women and men. Am. J. Epidemiol.165(11), 1265–1270 (2007).
   PubMedGoogle Scholar
• Lambe M, Thorn M, Sparen P et al. Malignant melanoma: reduced risk associated with early childbearing and multiparity. Mel. Res.6, 147–153 (1996).
   PubMedGoogle Scholar
• Karagas MR, Zens MS, Stukel TA et al. Pregnancy history and incidence of melanoma in women: a pooled analysis. Cancer Causes Control17(1), 11–19 (2006).
   PubMed Web of Science ®Google Scholar
• Driscoll MS, Grant-Kels JM. Nevi and melanoma in the pregnant woman. Clin. Dermatol.28(3), 287–292 (2010).
   PubMedGoogle Scholar
• Brinton LA, Moghissi KS, Westhoff CL, Lamb EJ, Scoccia B. Cancer risk among infertile women with androgen excess or menstrual disorders (including polycystic ovary syndrome). Fertil. Steril.94(5), 1787–1792 (2010).
   PubMed Web of Science ®Google Scholar
• Ishida H, Wada K, Masuda T et al. Critical role of estrogen receptor on anoikis and invasion of squamous cell carcinoma. Cancer Sci.98, 636–643 (2007).
   PubMed Web of Science ®Google Scholar
• Dobos J, Timar J, Bocsi J et al. In vitro and in vivo antitumor effect of 2- methoxyestradiol on human melanoma. Int. J. Cancer112, 771–776 (2004).
   PubMed Web of Science ®Google Scholar
• Dobos J. [Endocrine factors influencing melanoma progression]. Magy Onkol.53(1), 47–50 (2009).
   PubMedGoogle Scholar
• Richardson B, Price A, Wagner M et al. Investigation of female survival benefit in metastatic melanoma. Brit. J. Dermatol.80(12), 2025–2033 (1999).
   Google Scholar
• Mueck AO, Seeger H. Breast cancer: are oestrogen metabolites carcinogenic? Maturitas57(1), 42–46 (2007).
   PubMed Web of Science ®Google Scholar
• Mao A, Paharkova-Vatchkova V, Hardy J, Miller MM, Kovats S. Estrogen selectively promotes the differentiation of dendritic cells with characteristics of Langerhans cells. J. Immunol.175(8), 5146–5151 (2005).
   PubMed Web of Science ®Google Scholar
• Krahn-Bertil E, Dos Santos M, Damour O, Andre V, Bolzinger MA. Expression of estrogen-related receptor β (ERRβ) in human skin. Eur. J. Dermatol.20(6), 719–723 (2010).
   PubMed Web of Science ®Google Scholar
• Mor G, Sapi E, Abrahams VM et al. Interaction of the estrogen receptors with the Fas ligand promoter in human monocytes. J. Immunol.170(1), 114–122 (2003).
   PubMed Web of Science ®Google Scholar
• Widyarini S, Domanski D, Painter N, Reeve VE. Estrogen receptor signaling protects against immune suppression by UV radiation exposure. Proc. Natl Acad. Sci. USA103, 12837–12842 (2006).
   PubMedGoogle Scholar
• Cho J, Allanson M, Reeve VE. Oestrogen receptor-β signalling protects against transplanted skin tumor growth in the mouse. Photochem. Photobiol. Sci.9, 608–614 (2010).
   PubMedGoogle Scholar
• De Giorgi V, Mavilia C, Massi D et al. Estrogen receptor expression in cutaneous melanoma. Arch. Dermatol.145(1), 30–33 (2009).
   PubMedGoogle Scholar
• Schmidt AN, Nanney LB, Boyd AS et al. Oestrogen receptor-β expression in melanocytic lesions. Exp. Dermatol.15, 971–980 (2006).
   PubMedGoogle Scholar
• Ohata C, Tadokoro T, Itami S. Expression of estrogen receptor β in normal skin, melanocytic nevi and malignant melanoma. J. Dermatol.35, 215–221 (2008).
   PubMed Web of Science ®Google Scholar
• Matsuoka H, Tsubaki M, Yamazoe Y et al. Tamoxifen inhibits tumor cell invasion and metastasis in mouse melanoma through suppression of PKC/MEK/ERK and PKC/PI3K/Akt pathways. Exp. Cell Res.315(12), 2022–2032 (2009).
   PubMedGoogle Scholar
• Dewhurst LO, Gee JW, Rennie IG, MacNeil S. Tamoxifen, 17β-oestradiol and the calmodulin antagonist J8 inhibit human melanoma cell invasion through fibronectin. Br. J. Cancer75(6), 860–68 (1997).
   PubMed Web of Science ®Google Scholar
• Cocconi G, Bella M, Calabresi F et al. Treatment of metastatic malignant melanoma with decarbazine plus tamoxifen. N. Engl. J. Med.327, 516–523 (1992).
   PubMed Web of Science ®Google Scholar
• Rusthoven JJ, Quirt IC, Iscoe NA et al. Randomized, double-blind, placebo controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. J. Clin. Oncol.14, 2083–2090 (1996).
   PubMed Web of Science ®Google Scholar
• Agarwala SS, Ferri W, Gooding W, Kirkwood JM. A Phase III randomized trial of dacarbazine and carboplatin with and without tamoxifen in the treatment of patients with metastatic melanoma. Cancer85, 1979–1984 (1999).
   PubMed Web of Science ®Google Scholar
• Falkson CI, Ibrahim J, Kirkwood JN, Coates AS, Atkins MB, Blum RH. Phase III trial of dacarbazine versus dacarbazine with interferon-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group Study. J. Clin. Oncol.16, 1743–1751 (1998).
   PubMed Web of Science ®Google Scholar
• Creagan ET, Suman VJ, Dalton RJ et al. Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma. J. Clin. Oncol.17, 1884–1890 (1999).
   PubMed Web of Science ®Google Scholar
• Lens MB, Reiman T, Husain AF. Use of tamoxifen in the treatment of malignant melanoma. Cancer98, 1355–1361 (2003).
   PubMed Web of Science ®Google Scholar
• de Giorgi V, Gori A, Grazzini M et al. The initiation and progression of melanoma: estrogens or estrogen receptors? Mel. Res.20(1), 64–65 (2010).
   PubMedGoogle Scholar
• de Giorgi V, Mavilia C, Massi D et al. The role of estrogens in melanoma and skin cancer. Carcinogenesis30(4), 720 (2009).
   PubMedGoogle Scholar
• Bardin A, Boulle N, Lazennec G, Vignon F, Pujol P. Loss of ER{β} expression as a common step in estrogen-dependent tumor progression. Endocr. Relat. Cancer11(3), 537–551 (2004).
   PubMed Web of Science ®Google Scholar